SPf66: The first and towards the second generation of malarial vaccines

Malaria: Molecular and Clinical Aspects

Volumn , Issue , 1999, Pages 541-554

  Patarroyo, Manuel E ^a   Amador, Roberto ^a  

^a UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 2042515299     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (50)

1. Alonso, P.L., Teuscher, T. and Tanner, M. (1994a). SPf66: Research for development or development of research? Vaccine, 12, 99–101.
2. Alonso, P.L., Tanner, M., Smith, T., Hayes, RJ., Schellenberg, J.R.M., Lopez, M.C. et al. (1994b). A trial of the synthetic malaria vaccine SPf66 in Tanzania: rationale and design. Vaccine, 12, 181–186.
3. Alonso, P.L., Smith, T. and Armstrong-Schellenberg, J.R.M. (1994c). Randomised trial of efficacy of SPf66 vaccine against Plasmodiumfalciparum malaria in children in southern Tanzania. Lancet, 344,1175–1181.
4. Alonso, P.L., Smith, T.A., Armstrong-Schellenberg, J.R.M., Kitua, AY., Masanja, H., Hayes, R. et al. (1996) Duration of protection and age-dependence of the effects of the SPf66 Malaria vaccine in African Children exposed to intense transmission of Plasmodium falciparum. J. Inject. D., 174, 367–72.
5. Alonso, P.L., Clopez, M., Bordmann, G., Smith, T A., Aponte J.J., Weiss, N.A et al. (1997). Immune responses to Plasmodium falciparum antigens during a malaria vaccine trial in Tanzanian children. Parasite Immunol., 19 (in press).
6. Amador, R., Moreno, A., Valero, M.V., Murillo, L.A, Mora, AL., Rojas, M. et al. (1992a). The first field trials of the chemically synthesised malaria vaccine SPf66: safety, immunogenicity and protectivity. Vaccine, 10, 179–184.
7. Amador, R., Moreno, A., Murillo, L.A., Sierra, O., Saavedra, D., Mora, A.L. et al. (1992b). Safety and immunogenicity of the synthetic malaria vaccine SPf66 in a large field trial. J. Infect. Dis., 166, 139–144.
8. Anders, R.F. (1986). Multiple cross-reactivities amongst antigens of Plasmodium falcip arum impair the development of protective immunity against malaria. Parasite Immunol., 6, 529–539.
9. Ballou, W.R. (1995). Clinical trials of Plasmodium falciparum erythrocytic stage vaccines. Am. J. Trop. Med. Hyg., 50, 59–65, 1995.
10. Beck, H.P., Felger, I., Buwagan, T, Genton, B., Alexander, N., Jazwinska, E. et al. (1995). Evidence of HLA class II association with antibody reponse against the malaria vaccine SPf66 in a naturally exposed population. Am. J. Trop. Med. Hyg., 3, 284–288.
11. Beck, H.P., Felger, I., Huber, W., Steiger, S. and Smith, T (1997). Analysis of multiple Plasmodiumfalciparum infections in Tanzanian children during the phase III trial of the malarial vaccine SPf66. J. Inject. Dis., 175, 921–926.
12. Biggs, B.A., Anders, R.F., Dillon, H.E., Davern, KM., Martin, M., Petersen, C. and Brown, G.V. (1992). Adherence of infected erythrocytes to venular endothelium selects for antigenic variants of Plasmodium falciparum. J. Immunol., 149, 2047–2054.
13. Bothamley, G.H., Beck, J.S., Potts, R.C., Grange, J.M., Kardjito, T. and Ivanyi, J. (1992). Specificity of antibodies and tuberculin response after occupational exposure to tuberculosis. J. Infect. Dis., 166, 182–186.
14. Camus, D. and Hadley, TJ.A. (1985). Plasmodium falciparum antigens that bind to host erythrocytes and merozoites. Science, 230, 553.
15. Carlson, J., Helmby, H., Hill, A, Brewster, D., Greenwood, B.M. and Wahlgren, M. (1990). Human cerebral malaria: association with erythrocyte rosetting lack of anti-rosetting antibodies. Lancet, 336, 1457–1460.
16. Caspers, P., Gentz, R., Matile, H., Pink, J.R. and Sinigaglia, F. (1989). The circumsporozoite protein gene from NF54, a Plasmodiumfalciparum isolate used in malaria vaccine trials. Mol. Biochem. Parasitol., 35, 185— 189.
17. Day, KP. and Marsh, K. (1991). Naturally acquired immunity to Plasmodium falciparum. Immun. Today, 12, 68–71.
18. Deloron, P., Campbell, G.H., Brandling-Bennett, D., Roberts, J.M., Schwartz, I.K, Odera, J.S. et al. (1989). Antibodies to Plasmodium falciparum ring-infected erythrocyte surface antigen and P. falciparum and P. malariae circumsporozoite proteins: seasonal prevalence in Kenyan villages. Am. J. Trop. Med. Hyg., 41, 395–399.
19. Delplace, P., Bhatia, A, Cagnard, M., Camus, D., Colombet, G., Debrbant, A et al. (1988). Protein p126: a parasitophorous vacuole antigen associated with the release of Plasmodiumfalciparum merozoites. Biol. Cell, 64, 215–221.
20. D’Alessandro, U., Leach, A., Drakely, Ch.J., Bennett, S., Olaleye, B.O., Fegan, G.W. et al. (1995). Efficacy trial of malaria vaccine SPf66 in Gambian infants. Lancet, 146, 462–467.
21. Graves, P. (1997). Human malaria vaccines. In: Garner, P., Gelband, H., Olliario, P., Salinas, R. (eds.) Infectious Diseases Module of The Cochrane Database of Systematic Reviews, (Updated 04 December, 1996). The Cochrane Library [database on disk and CDROM]. The Cochrane Collaboration, Issue 1. Oxford: Updated Software; Updated quarterly.
22. Hui, G.S.N. (1994). Liposomes, muramyl dipeptide derivatives, and nontoxic lipid A derivatives as adjuvants for human malaria vaccines. Am. J. Trop. Med. Hyg., 50, 41–51.
23. Kensil, C.R., Newman, M.J., Coughlin, R.T., Soltysik, S., Bedore, D., Recchia, J. et al. (1995). The use of Stimulon adjuvant to boost vaccine response. Vacc. Res., 2, 273–281.
24. Kochan, J., Perkins, M.E. and Ravetch, J.V. (1985). A tandemly repeated sequence determines the binding domain for an erythrocyte receptor-binding protein of Plasmodium falciparum. Cell, 44, 689.
25. Marsh, K and Howard, R.J. (1986). Antigens induced on erythrocytes by Plasmodiumfalciparum: Expression of diverse and conserved determinants. Science, 231, 150–153.
26. Molano, A, Segura, C., Guzman, E, Lozada, D. and Patarroyo, M.E. (1992). In human malaria protective antibodies are directed mainly against the Lys-Glu ion pair within the Lys-Glu-Lys motif of the synthetic vaccine SPf66. Parasite Immunol., 14, 111–124.
27. Murillo, L.A, Rocha, C.L., Mora, AL., Kalil, J., Goldemberg, AK and Patarroyo, M.E. (1992a). Molecular analysis of each HLA DR4 B-1 gene in malaria vaccines. Typing and subtyping by PCR technique and oligonucleotides. Parasite Immunol., 13, 201–210.
28. Murillo, L.A., Tenjo, E, Clavijo, O., Orozco, M., Sampaio, S., Kalil, J. and Patarroyo, M.E. (1992b). A specific T cell-receptor genotype preference in the immune response to a synthetic Plasmodiumfalciparum malaria vaccine. Parasite Immunol., 14, 87–94.
29. Nosten, E, Luxemburger, Ch., Kyle, D.E., Ballou, W.R., Wittes, J., Wah, Eh. et al. (1996). Randomised doubleblind placebo-contolled trial of SPf66 malaria vaccine in children in northwestern Thailand. Lancet, 348, 701–707.
30. Noya, O., Gabaldon, I., de Noya, B., Borges, R., Zerpa, N., Urbaez, J.D. et al. (1993). A population-based clinical trial with the SPf66 synthetic Plasmodium falciparum malaria vaccine, in Venezuela. J. Inject. Dis., 170, 396–402.
31. Patarroyo, G., Franco, L.C., Amador, R., Murillo, L.A., Rocha, C.L., Rojas, M. et al (1992). Study of the safety and immunogenicity of the synthetic malaria SPf66 vaccine in children aged 1–14 years. Vaccine, 10, 175–178.
32. Patarroyo, M.E., Amador, R., Clavijo, P., Moreno, A., Guzman, E and Romero, P. (1988). A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum malaria. Nature, 332, 158–161.
33. Perkins, M.E. and Rocco, L.J. (1988). Sialic acid-dependent binding of Plasmodium falciparum merozoite surface antigen, Pf200, to human erythrocytes J. Immunol., 141, 3190.
34. Perlmann, H., Berzins, K., Wahlgren, M., Carlsson, J., Bjorkman, A., Patarroyo, M.E. et al. (1984). Antibodies in malarial sera to parasite antigen in the membrane of erythrocytes infected with early asexual stages of Plasmodium falciparum. J. Exp. Med., 159, 1686–1704.
35. Rocha, C.L., Murillo, L.A., Mora, A.L., Rojas, M., Franco, L.C., Cote, J. et al. (1992). Determination of the immunization schedule for field trials with the sybthetic malaria vaccine SPf66. Parasite Immunol., 14, 95–109.
36. Rogers, W.O., Malik, A., Mellouk, S., Nakamura, K., Rogers, M.D., Szarfman, A. et al. (1992). Characterization of Plasmodium falciparum sporozoite surface protein 2. PNAS, 89, 9176–9180.
37. Salcedo, M., Barreto, L., Rojas, M., Moya, R., Cote, J. and Patarroyo, M.E. (1991). Studies on the humoral immune response to a synthetic vaccine against Plasmodium falciparum malaria. Clin. Exp. Immunol., 84, 122–128.
38. Schofield, L. and Uadia, P. (1990). Lack of Ir gene control in the immune response to malaria. I. A thymus independent antibody response to the repetitive surface protein of sporozoites. J. Immunol., 144(7), 2781–2788.
39. Sempertegui, E, Estrella, B., Moscoso, J., Piedrahita, C.L., Hernandez, D., Gaybor, J. et al. (1994). Safety, immunogenicity and protective effect of the SPf66 malaria synthetic vaccine against Plasmodiumfalciparum infection in randomized double-blind placebo-controlled field trial in an endemic area of Ecuador. Vaccine, 12, 337–342.
40. Sim, B.K.L., Chitni, B.K.L., Chitnis, C.E., Wasniowska, K., Hadley, TJ. and Miller, L.H. (1994). Receptor and Ligand Domains for invasion of Erythrocytes by Plasmodium falciparum. Science, 264, 1941–1944.
41. Smythe, J.A., Coppel, R.L., Brown, G.V., Ramasamy, R., Kemp, D.J. and Anders, RE (1988). Identification of two integral membrane proteins of Plasmodium falciparum. PNAS, 85, 5195–5199.
42. Stanley, H.A., Howard, R.E. and Reese, RT. (1985). Recognition of a Mr 56kD glycoprotein on the surface of Plasmodium falciparum merozoites by mouse monoclonal antibodies. J. Immunol., 134, 3439–3444.
43. Trape, J. and Rogier, C. (1995). Efficacy of SPf66 vaccine, against Plasmodium falciparum malaria in children. Lancet, 345, 134–135.
44. Urquiza, M., Rodriguez, L.E., Suarez, J.E., Guzman, E, Ocampo, M., Curtidor, H. et al. (1996). Identification of peptides from the Plasmodium falciparum MSP-1 protein able to bind to red blood cells. Parasite Immunol., 18, 515–526.
45. Valero, M.V., Amador, R, Galindo, C., Figueroa, J., Bello, M.S., Murillo, L.A. et al. (1993). Vaccination with SPf66, a chemically synthesised vaccine, against Plasmodium falciparum malaria in Colombia. Lancet, 341, 705–710.
46. Valero, M.V., Amador, R, Aponte, J.J., Narvaez, A., Galindo, C., Silva, Y. et al. (1996). Evaluation of SPf66 malaria vaccine during a 22-month follow-up field trial in the Pacific coast of Colombia. Vaccine, 14, 1466–1470.
47. Wiihlin, B., Sjolander, A., Ahlborg, N., Udomsangpetch, R, Scherf, A., Mattei, D. et al. (1992). Involvement of Pf155/RESA and cross-reactive antigens in Plasmodium falciparum merozoite invasion in vitro. Inject. Immun., 60, 443–449.
48. WHO (1989). Malaria Action Programme: Guidelines for the evaluation of Plasmodium falciparum asexual blood-stage vaccines in populations exposed to natural infection. 1–34.
49. WHO (1992). Division of Control of Tropical Diseases: Outline for WHO’s plan of work for malaria control, 1993–2000. 1–21.
50. WHO (1995). Tropical disease research: progress, 1975–94: highlights, 1993–94: twelfth programme report of the UNDP World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TOR). 1: 57–76.